Form 8-K · Current report
Boston Scientific 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0000885725
- Accession no.
- 0000885725-26-000051
Summary
Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, up 7.5% on a reported basis and 7.0% operationally and organically, with GAAP earnings of $0.61 per share and adjusted EPS of $0.86. The company guided full-year 2026 organic sales growth to 5-6% and adjusted EPS to $3.28-$3.32, and said it invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire its TAVR business.
Key points
- Cardiovascular net sales grew 8.3% on a reported basis to $3.624 billion, while MedSurg grew 5.9% to $1.818 billion.
- Boston Scientific completed a previously announced $2 billion accelerated share repurchase program, repurchasing about 40 million shares.
- The company received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter.
- Third-quarter 2026 guidance was set at 3-5% reported and organic net sales growth and adjusted EPS of $0.80-$0.82.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On July 29, 2026, Boston Scientific Corporation issued a press release announcing financial results for the second quarter ended June 30, 2026. A copy of the release is furnished with this report as Exhibit 99.1. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.